These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22933705)

  • 21. Inhibition of human lung cancer proliferation through targeting stromal fibroblasts by dihydromyricetin.
    Fan KJ; Yang B; Liu Y; Tian XD; Wang B
    Mol Med Rep; 2017 Dec; 16(6):9758-9762. PubMed ID: 29039563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
    Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
    McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
    Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.
    Wei T; Zhang LN; Lv Y; Ma XY; Zhi L; Liu C; Ma F; Zhang XF
    Oncotarget; 2014 Nov; 5(21):10307-17. PubMed ID: 25333264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
    Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
    J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
    Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J
    J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development.
    Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
    Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis.
    Tsutsumi N; Yonemitsu Y; Shikada Y; Onimaru M; Tanii M; Okano S; Kaneko K; Hasegawa M; Hashizume M; Maehara Y; Sueishi K
    Circ Res; 2004 May; 94(9):1186-94. PubMed ID: 15059936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.
    Zhu CQ; Popova SN; Brown ER; Barsyte-Lovejoy D; Navab R; Shih W; Li M; Lu M; Jurisica I; Penn LZ; Gullberg D; Tsao MS
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11754-9. PubMed ID: 17600088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression analysis of platelet-derived growth factor receptor alpha and its ligands in the developing mouse lung.
    Gouveia L; Betsholtz C; Andrae J
    Physiol Rep; 2017 Mar; 5(6):. PubMed ID: 28330949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
    Coxon A; Ziegler B; Kaufman S; Xu M; Wang H; Weishuhn D; Schmidt J; Sweet H; Starnes C; Saffran D; Polverino A
    Mol Cancer; 2012 Sep; 11():70. PubMed ID: 22992329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
    Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
    J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 37. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
    Shikada Y; Yonemitsu Y; Koga T; Onimaru M; Nakano T; Okano S; Sata S; Nakagawa K; Yoshino I; Maehara Y; Sueishi K
    Cancer Res; 2005 Aug; 65(16):7241-8. PubMed ID: 16103075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.
    Dong J; Grunstein J; Tejada M; Peale F; Frantz G; Liang WC; Bai W; Yu L; Kowalski J; Liang X; Fuh G; Gerber HP; Ferrara N
    EMBO J; 2004 Jul; 23(14):2800-10. PubMed ID: 15229650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.